Results 241 to 250 of about 357,237 (305)

Checkpoint inhibitors, obinutuzumab plus PET‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)
Arina Martynchyk   +15 more
wiley   +1 more source

Combination antiretroviral therapy and the risk of myocardial infarction [PDF]

open access: yes, 2003
Abbadesse, V   +535 more
core  

CXCR4 Is a Potential Target for Anti-HIV Gene Therapy. [PDF]

open access: yesInt J Mol Sci
Prokopovich AK   +3 more
europepmc   +1 more source

Deciphering the full spectrum of Castleman diseases based on a cohort of 700 patients in a western country

open access: yesBritish Journal of Haematology, EarlyView.
The spectrum of Castleman diseases has expanded over the past three decades. The phenotype of the diseases varies not only among the three major types but also according to the patient ancestry. Summary Under the Castleman disease (CD) eponym, three distinct diseases sharing common pathological features have been described over time.
Eric Oksenhendler   +4 more
wiley   +1 more source

Building Metabolically Stable and Potent Anti-HIV Thioether-Lipid Analogues of Tenofovir Exalidex: A thorough Pharmacological Analysis. [PDF]

open access: yesJ Med Chem
D'Erasmo MP   +11 more
europepmc   +1 more source

Prodrug Strategy Extends the Use of Anti-HIV Sulfanylbenzamides for Application In Vivo. [PDF]

open access: yesACS Pharmacol Transl Sci
Robello M   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy